



🌐 When poll is active, respond at [PollEv.com/patrickryan800](https://poll-ev.com/patrickryan800)

What did you learn during Phenotype Phebruary 2023?

Top

No responses received yet. They will appear here...



What happened in Week 4

Phenotype Phebruary 2023 - P10 - Neonatal Hypoxic Ischemic Encephalopathy

General phenotype-phebruary

Gowtham_Rao 1 20d

In this thread, @Khyzer_Aziz will be leading us thru his teams experience going through Phenotype Development and Evaluation Process for Neonatal Hypoxic Ischemic Encephalopathy. This is anticipated to be a month long process. As he progresses he has agreed to make posts on this thread to describe his experience.

Week 1: we hope to have the target clinical idea described and have built 1 or more candidate cohort definitions.

Week 2: we attempt to instantiate the cohort on one or more data sources, and run CohortDiagnostics on it. Post the results in public domain.

Week 3: we will review the output from one or more data sources, and perform and evaluation. Based on the evaluation - we might revise the cohort definitions.

Week 4: we finalize the cohort definitions and have an evaluation document. This evaluation document can then be peer reviewed by the community. If accepted the phenotype will be then added to the OHDSI Phenotype Library.

Phenotype Phebruary 2023 - P11 - Neurofibromatosis type 1 with Optical Pathway Glioma


General phenotype-phebruary

MaximMoinat 2 21d

We have been allowed to submit a **bonus phenotype** for this Phenotype Phebruary. We would be hugely helped if the OHDSI community can help evaluating our phenotype. Evaluation is due on February 15th 2023.

We present here the Clinical Description, Literature research and Atlas Cohort Definitions for NF1 and NF1 with OPG. This effort is coming from EU-PEARL, a collaboration between academia and EFPIA around platform trials funded by Innovative Health Initiative. Neurofibromatosis (NF) is one of the selected disease areas. A validated, computable phenotype for NF would help in trial site selection through accurately retrieving patient counts. Within NF, we are specifically interested in developing a phenotype for *Optical Pathway Glioma (OPG)* as manifestation of NF is often not captured in detail in

Four Weeks. Four Debates. 10 Completed phenotypes = 10



2023
CALENDAR YEAR

FEBRUARY
CALENDAR MONTH

MONDAY
FIRST DAY OF WEEK

Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
20	21	22	23	24	25	26
P 10: Neonatal Hypoxic Ischemic Encephalopathy (Khyzer B Aziz, M.D.)	OHDSI Community Call		P 11: Optical Pathway Glioma (Maxim Moinat)			

<https://forums.ohdsi.org/t/phenotype-phebruary-2023-p10-neonatal-hypoxic-ischemic-encephalopathy/18189>

<https://forums.ohdsi.org/t/phenotype-phebruary-2023-p11-neurofibromatosis-type-1-with-optical-pathway-glioma/18236>

Observational Health Data Sciences and Informatics (OHDSI, pronounced "Odyssey") is an international community of stakeholders committed to bring the value of health data through large-scale analytics. If you are a new member-- Welcome! Tell us a bit about yourself on the General forum and know how we can help. Learn more at www.ohdsi.org

Phenotype Phebruary 2023 - Week 4 – Discussion – How can we couple probabilistic and rule based phenotyping in a systematic process to improve the development and evaluation of phenotypes?

General phenotype-phebruary

Continued evaluation: Parkinson's Disease, Dermatomyositis, ST Elevated Myocardial Infarction



What happened during Phenotype Phebruary 2023

<https://www.ohdsi.org/phenotype-phebruary-2023/>

Respond at [PollEv.com/patrickryan800](https://www.poll-ev.com/patrickryan800)

What do you want to see accomplished during Phenotype Phebruary 2023?

Top

- 13 — Comparisons with non-OHDSI phenotypes
- 10 — Phenotypes done
- 8 — Phenotypes with sophisticated logic (as opposed to just presence of a code from a concept set)
- 8 — Looking at differences in phenotype definitions across data partners
- 8 — Demonstration of the utility of diagnostics
- 7 — Lots of participation from new members

Who We Are | Updates & News | Standards | Software Tools | Network Studies | Community Forums | Education | New To OHDSI | Community Calls | Events | Workgroups | Our Journey: Where We Have Been & Where We Are Going (PDF) | Community Dashboards | This Week In OHDSI | Support & Sponsorship | APAC 2023 | Github | YouTube | Twitter | LinkedIn | Newsletters

Phenotype Phebruary 2023: How To Join The Effort

The schedule to the left lists the phenotypes that will be investigated throughout the month, along with the respective leads and reviewers. Check for updates to this graphic as more people join the effort. The graphic to the right highlights the four debates/discussions around phenotyping that are happening this month. Please use the forum links below to join any of these activities.


"Phenotype Phebruary" is a community-wide initiative to both develop and evaluate phenotypes for health outcomes that could be investigated by

Week 3 Update





Phenotype Phebruary 2023 in numbers

- **11** phenotypes discussed in the forums
 - 5 phenotypes finished peer review --> library
 - 5 phenotypes developed, evaluated and on their way to peer review
- **4** debates/discussions addressed
- **7** shiny apps on data.ohdsi.org
- **32** collaborators interacted in the forums or attended calls
- **9 Publications**
 - **8** applied publications planned
 - **1** methods publication



(Feb. 8) Allan Wu, MD, discusses his approach to replicate a published phenotype algorithm on OHDSI tools. He presents two phenotype algorithms, a) Unanimity definition, and b) Tiered consensus algorithm in Atlas. Unanimity definition demonstrates the use of future events to attain high specificity in the definition. Tiered consensus algorithm requires use of provider specialty that may need creative solutions. The group agreed to move the Unanimity definition to an OHDSI network study which continues to iterate on Tiered consensus definition.

(Feb. 8) Christopher Mecoli, MD, and team demonstrated progress in the development of a cohort definition for Inflammatory Dermatosyositis at Johns Hopkins University. The team discussed their experience running Cohort Diagnostics, and reviewed the results on data.ohdsi.org. They discussed the impact of design choices, specifically the use of lab values in cohort definitions. Decisions were made to improve the cohort definition logic.





Moving forward – Agenda for 2023

--> OHDSI Phenotype Development and Evaluation Workgroup

id	Publication topic	lead
P1	Multi-database evaluation and probabilistic reference standard validation of phenotype definitions for acute pancreatitis	<i>Jamie Weaver, Evan Minty</i>
P2	Capture of Acute Anaphylaxis events in observational data and its use in safety surveillance	<i>Andrea Noel</i>
P3	Phenotype development and evaluation of Appendicitis in a network of observational data	<i>Evan Minty</i>
P4	Development and evaluation of phenotype algorithms for designated medical events in a network of real-world data.	<i>Designated Medical Event</i>
P7	Application of rare disease Adult Dermatomyositis phenotype definition on general observational data and specialized disease registry	<i>Christopher Mecoli</i>
P8	Evaluation of Parkinsons Disease on observational data along with chart review using strategic sampling	<i>Alan Wu</i>
P9	Phenotype development and evaluation of ST Elevated Myocardial Infarction in a network of observational data	<i>Mirza Khan</i>
P10	Phenotype development and evaluation of Hypoxic Ischemic Encephalopathy among Neonates in a network of observational data	<i>Khyzer Aziz, Evan Minty</i>
P11	Phenotype development and evaluation of Optical Pathway Glioma among Neonates in a network of observational data	<i>Maxim Moniat</i>
Method	Phenotype development and evaluation in the context of observation network study: learnings from the OHDSI community "Phenotype Phebruary" .	<i>Azza Shoaibi, Gowtham Rao</i>



OHDSI Phenotype Development and Evaluation Workgroup

- **Phenotype Phebruary 2023 has set the agenda for the OHDSI Phenotype Development and Evaluation workgroup**
- **Come join us**

Objective 1: Harden Phenotype Development and Evaluation framework

- Enable the community to complete 10 phenotypes via the current phenotype development and evaluation process using activities like Phenotype Phebruary (Timeline: 1Q 2023)
- Through scientific debate address at least 4 topics of community interest and drive community consensus (Timeline: 2Q 2023)
- Clarify terminology and scientific definitions and deliver a document that organizes such ideas (Timeline: 2Q 2023)
- Integrate probabilistic phenotyping into the OHDSI PL (Timeline: 3Q 2023)
- Write two scientific papers on phenotyping development and evaluation (Timeline: 4Q 2023)

Objective 2: Improve collaboration by enabling community wide participation on Phenotype Development and Evaluation

- In Phenotype Phebruary have 10 Phenotypes completed and published in OHDSI Phenotype library as peer reviewed Cohort Definitions (Timeline: 1Q 2023)
- Promote clinically trained scientists by having at least 5 new clinician collaborators actively engage in Phenotype Phebruary (Timeline: 1Q 2023)

Objective 3: Promote the usage of OHDSI Phenotype library

- Complete peer review for 10 (phenotype phebruary) + 10 (additional) phenotypes added to the OHDSI Phenotype Library. (Timeline: 4Q 2023)
- Formalize submission process and perform at least 2 communication sessions on OHDSI Phenotype Library. (Timeline: 2Q 2023)
- Execute at least two OHDSI Studies that uses the Cohort Definitions in the OHDSI Phenotype library to generate characterization evidence (Timeline: 3Q 2023)
- Write a scientific paper on OHDSI Phenotype Library (Timeline: 4Q 2023)

What did you learn during Phenotype Phebruary 2023?

Top

No responses received yet. They will appear here...

Community Reflections